At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Open Label Trial to Assess Safety of BIBW 2992 With Vinorelbine in Solid Tumors Known to Overexpress HER2 and/or EGFR
In Brief
A Phase 1 clinical trial evaluating BIBW 2992 low (20mg) dosage, BIBW 2992 medium (40mg) dosage, and 4 other interventions for Neoplasms. Completed, enrolled 55 participants across 2 sites.
Detailed Summary
To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine
Study Details
Timeline
Interventions
Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
Patients will receive 80 mg/m² Vinorelbine per os at J22
Patients will receive 25 mg/m² of Vinorelbine i.v.